{"schema_version":"secwatch.filing_event.v1","accession":"0000059478-25-000202","form_type":"8-K","ticker":"LLY","cik":"0000059478","company_name":"ELI LILLY & Co","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.143503+00:00","generated_at":"2026-05-17T18:36:00.251335+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lilly Q2 revenue $15.56B (+38% YoY), EPS $6.29 (+92%), raises FY guidance","bullets":["Q2 revenue $15.56B, up 38% YoY, driven by volume growth from Zepbound and Mounjaro.","Reported EPS $6.29, up 92%; non-GAAP EPS $6.31, up 61%, both inclusive of $0.14 IPR&D charges.","Full-year revenue guidance raised $1.5B to $60-62B; reported EPS guided $20.85-22.10; non-GAAP EPS $21.75-23.00.","Pipeline progress: positive results for orforglipron in obesity, Mounjaro SURPASS CVOT in T2D and heart disease, and Jaypirca vs Imbruvica in CLL/SLL.","Completed acquisitions of SiteOne Therapeutics and Verve Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0000059478-25-000202","json":"https://secwatch.observer/filing/0000059478-25-000202.json","markdown":"https://secwatch.observer/filing/0000059478-25-000202.md","text":"https://secwatch.observer/filing/0000059478-25-000202.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000202/0000059478-25-000202-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/59478/000005947825000202/lly-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:36:00.251335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}